NRD305CN

Phase III Study of NRD101: A confirmatory study of NRD101 in patients with periarthritis scapulohumeralis

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2080223475

Enrollment

260

Registered

2017-03-10

Start date

2017-07-05

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Periarthritis scapulohumeralis

Interventions

investigational material(s) Generic name etc : NRD101 INN of investigational material : - Therapeutic category code : 399 Agents affecting metabolism, n.e.c. Dosage and Administration for Investigatio

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: (1) Patients who have been diagnosed with periarthritis scapulohumeralis based on clinical conditions. (2) Limitation of movement, signs and symptoms lasting for 12 or more weeks.

Exclusion criteria

Exclusion criteria: (1) Other diseases with shoulder joint dysfunctions, such as rotator cuff tear, acute calcific tendinitis. (2) Patients not appropriate for pharmacotherapy.

Design outcomes

Primary

Measure	Time frame
efficacy NRS pain score Variation of score	—

Secondary

Measure	Time frame
efficacy Overall improvement Transition in pain score	—

Countries

Asia except Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026